Clinical Trial

A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

Study acronym: RAMP201J
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will confirm the safety and efficacy of avutometinib in combination with defactinib in Japanese patients with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-11-07; most recent amendment 2025-12-15.
Status change: Recruiting → Active, Not Recruiting 2025-12-15
Trial Details
NCT Number NCT06682572
Lead Sponsor Verastem, Inc.
Collaborators: Japanese Gynecologic Oncology Group
Conditions Low Grade Serous Ovarian Cancer, Ovarian Cancer
Enrollment 16 participants
Start Date 2024-10-30
Primary Completion 2025-12 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2025-12-17